Download our whitepaper,

Ovarian Cancer Clinical Trials:
Epidemiology, Biomarkers, and
Therapeutic Strategies

What's Inside:

  • Epidemiology and risk factor assessment for ovarian cancer.
  • Endpoints for progression-free and overall survival.
  • Role of PARP inhibitors and targeted therapies.
  • Patient selection and biomarker-driven enrollment.
  • Combination therapy design and maintenance studies.
  • Regulatory and ethical considerations in women’s health trials.

Access your complimentary whitepaper today:






    Ovarian Cancer

    Ovarian cancer, a multifaceted and potentially lethal malignancy, is the fifth leading cause of cancer-related deaths among women and constitutes a significant health challenge globally.

    Ovarian cancer predominantly affects women in postmenopausal stages, although it can occur at any age. The insidious nature of its development, often asymptomatic in the early stages, leads to late diagnosis and a consequently poorer prognosis. The foundational knowledge covered in this whitepaper is critical for healthcare professionals, researchers, and scientists as it shapes clinical approaches and research directions.

    5th

    Ovarian cancer ranks 5th in female cancer deaths globally

    90%

    Approximately 90% of ovarian cancers originate from epithelial cells

    BRCA1 & BRCA2

    mutations increase the risk of ovarian cancer, with carriers having up to a 40% lifetime risk

    Our clinical team has over

    120

    years of combined clinical trial experience